Cytosorbents logo
Cytosorbents
CTSO | NASDAQ
Chart Builder DCF Calculator
$4.85
-$0.02 (-0.41%)
At close: Nov 16, 2026, 4:00 PM ET
$4.85
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Cytosorbents Company Profile

Company profile explained

Company Profile

Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.

Key Executives

Name Position
Phillip Chan Chief Executive Officer & Director
Peter J. Mariani Chief Financial Officer
Vincent J. Capponi President & Chief Operating Officer
Christian Steiner Executive Vice President of Sales & Marketing
Christopher Cramer Senior Vice President of Business Development
Efthymios N. Deliargyris FACC FESC FSCAI Chief Medical Officer
Jodi Hoover Executive
Kathleen Bloch Advisor
Robert H. Bartlett Co-Chairman of Cardiac Surgery Advisory Board & Consultant

Latest SEC Filings

Date Type Title
Sep 23, 2026 8-K Current Report
Sep 16, 2026 4 Filing
Sep 16, 2026 4 Filing
Sep 16, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 08, 2026 8-K Current Report
Aug 14, 2026 8-K Current Report
Aug 07, 2026 8-K Current Report
Aug 06, 2026 8-K Current Report
Aug 06, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Cytosorbents
Cytosorbents logo
Country United States
IPO Date Aug 8, 2006
Industry Medical - Devices
Sector Healthcare
Employees 129
CEO Phillip Chan

Contact Details

305 College Road East Princeton, New Jersey 08540 United States

Stock Details

Ticker Symbol CTSO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001175151
CUSIP Number 23283X305
ISIN Number US23283X3052
SIC Code 3841

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.